Do you want to read an article? Please log in or register.
Standardized Approach to Treatment of Retinal Artery Occlusion After Intra-Arterial Injection of Soft-Tissue Fillers: EYE-CODE
Retinal Diseases
Related content
Retinal Diseases
Central retinal artery occlusion - a new, provisional treatment approach
Surv Ophthalmol.
Chronopoulos A, Schutz JS
Macular Diseases
Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab
Clin Exp Ophthalmol.
Spooner K, Fraser-Bell S, Hong T, Chang A
doi: 10.1111/ceo.13636.
Retinal Diseases
Risk factors for acute choroidal ischemia after intra-arterial melphalan for retinoblastoma: the role of the catheterization approach
Ophthalmology
Stathopoulos C, Bartolini B, Marie G, Beck-Popovic M, Saliou G, Munier FL
doi: 10.1016/j.ophtha.2020.09.021
COMMENTED
Retinal Diseases
Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Br J Ophthalmol
Gale R, Gill C, Pikoula M, Lee AY, Hanson RLW, Denaxas S, Egan C, Tufail A, Taylor P, UK EMR Database Users Group.
doi: 10.1136/bjophthalmol-2020-317306
COMMENTED
Macular DiseasesRetinal Diseases
Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER
★ 2
Recommended by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Ophthalmology
Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Holz FG, Korobelnik JF, Kim IK, Pruente C, Murray TG, Heier JS
doi: 10.1016/j.ophtha.2020.11.011
COMMENTED
Macular DiseasesRetinal Diseases
Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion
J Ophthalmol.
Nghiem-Buffet S, Glacet-Bernard A, Addou-Regnard M, Souied EH, Cohen SY, Giocanti-Auregan A
doi: 10.1155/2018/8656495.
Macular DiseasesRetinal Diseases
Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial
Ophthalmol Retina.
Vader MJC, Schauwvlieghe AME, Verbraak FD, Dijkman G, Hooymans JMM, Los LI, Zwinderman AH, Peto T, Hoyng CB, van Leeuwen R, Vingerling JR, de Jong-Hesse Y, van Lith-Verhoeven JJC, Dijkgraaf MGW, Schlingemann RO, Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) Study Group.
doi: 10.1016/j.oret.2019.12.019.
Macular Diseases
Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion
Ophthalmol Retina.
Yiu G, Welch RJ, Wang Y, Wang Z, Wang PW, Haskova Z
doi: 10.1016/j.oret.2019.08.009.
COMMENTED
Retinal Diseases
PROPHYLACTIC LASER TREATMENT TO DECREASE THE INCIDENCE OF RETINAL DETACHMENT IN FELLOW EYES OF IDIOPATHIC GIANT RETINAL TEARS
Retina.
Verhoekx JSN, van Etten PG, Wubbels RJ, van Meurs JC, van Overdam KA
doi: 10.1097/IAE.